Alternate-Day Buprenorphine Administration. Phase VII - 8
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000226
Collaborator
University of Vermont (Other)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Alternate-Day Buprenorphine Administration. Phase VII
Study Start Date
:
Nov 1, 1994
Outcome Measures
Primary Outcome Measures
- Drug use []
- Opioid withdrawal []
- Opioid agonist effects []
- Pupil diameter []
Eligibility Criteria
Criteria
Ages Eligible for Study:
21 Years
to 48 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Treatment Research Center | Burlington | Vermont | United States | 05401 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- University of Vermont
Investigators
- Principal Investigator: Warren Bickel, Ph.D., University of Vermont
Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000226
Other Study ID Numbers:
- NIDA-06969-8
- R01-06969-8
First Posted:
Sep 21, 1999
Last Update Posted:
Jun 24, 2005
Last Verified:
Jul 1, 1996